Advertisement

Advertisement
Breast Cancer

T-DXd Effective for Breast Tumors With HER2-Low and HER2-Ultralow Expression in Earlier Line of Therapy

In patients with hormone receptor–positive metastatic breast cancers with HER2-low or HER2-ultralow expression, treatment with the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) was found to be superior to chemotherapy after one or more lines of endocrine therapy. In DESTINY-Breast06, this approach significantly reduced the risk of disease progression by 38%, compared with chemotherapy, and patients with HER2-ultralow expression appeared to derive as much benefit as those in the HER2-low subset.

Multiple Myeloma

What Is the Better Target for Bispecific Antibodies in Multiple Myeloma: BCMA or GPRC5D?

For relapsed or refractory multiple myeloma, there are three available bispecific antibodies—two that target B-cell maturation antigen (BCMA) and one that targets G protein–coupled receptor class C group 5 member D (GPRC5D). Which is the preferred target? This question was addressed at the 2024 Debates and Didactics in Hematology and Oncology conference by two myeloma experts from Emory University Winship Cancer Center,1 which sponsors the annual event. Ajay K. Nooka, MD, MPH, Professor and Director of the Myeloma Program, and Nisha S. Joseph, MD, Associate Professor, both of the Department of Hematology and Medical Oncology at Emory, reviewed the data from pivotal trials that may inform clinicians in their treatment selection.

Leukemia

Discontinuation of CML Therapy: Which Patients Are Ideal Candidates?

With the introduction of tyrosine kinase inhibitors, chronic myeloid leukemia (CML) has become a chronic disease for most patients. Furthermore, we now know that some patients can successfully stop treatment and remain in remission.


Advertisement
Bladder Cancer

Nivolumab Plus Chemotherapy Extends Survival in Lymph Node–Only Metastatic Urothelial Cancer

The combination of nivolumab plus gemcitabine/cisplatin chemotherapy achieved high response rates and durable responses and improved overall survival and progression-free survival compared with gemcitabine/cisplatin chemotherapy alone in patients with urothelial carcinoma and clinical evidence of lymph node–only metastases (ie, cN+ urothelial cancer), providing optimism that patients with this type of urothelial carcinoma may achieve long-term remission. These findings were based on a post hoc subset analysis of the phase III CheckMate 901 trial presented at the 2024 ASCO Annual Meeting.

 

Lung Cancer

Inoperable Stage III NSCLC: Adaptive Radiotherapy Based on FDG-PET Tumor Residual Uptake

In a French phase II study (RTEP7–IFCT-1402) reported in The Lancet Oncology, Vera et al found that adaptive radiotherapy based on fluorine F-18–labeled fluorodeoxyglucose (FDG)–positron-emission tomography (PET) residual uptake appeared to improve local disease control compared with standard radiotherapy in patients with inoperable stage III non–small cell lung cancer (NSCLC).

Advertisement
Advertisement




Sponsored Content

SPONSORED BY THE BREAST CANCER INDEX® TEST BIOTHERANOSTICS, INC. A HOLOGIC COMPANY

Extended Endocrine Therapy for Early-Stage Hormone Receptor–Positive Breast Cancer: Tools for Decision-Making

More Top Stories


Hematologic Malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Geriatric Oncology

Too Much, Too Little, Just Right: Optimizing Cancer Care for Older Adults

Imagine walking into a fancy restaurant only to find a menu consisting mostly of kids’ dishes. It would make no sense. Just 25% of restaurant diners are younger than age 12, and they rarely write Yelp reviews. But when it comes to cancer treatment, this is not very far from what we do. The median...

Advertisement

Addition of ICIs to Neoadjuvant Chemotherapy for Early Breast Cancer

In a meta-analysis reported in JAMA Oncology, Villacampa et al found that the addition of neoadjuvant immune checkpoint inhibitor (ICI) treatment to chemotherapy was associated with improved outcomes among subgroups of patients with early breast cancer.   Study Details A literature search through...

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

Global Cancer Care

IDEA Awardees’ Reflections on the 2024 ASCO Annual Meeting

It happened! We received the International Development and Education Award (IDEA) from Conquer Cancer®, the ASCO Foundation, and it was a journey of growth, global collaboration, leadership, mentorship, and more. We have much to share after this breakthrough in our careers. The ASCO Annual Meeting...

Breast Cancer

A Diagnosis of Triple-Negative Breast Cancer Was Not on My Radar

Despite the fact that there is no history of breast cancer in my family, I didn’t take that good fortune for granted and was diligent about getting my regularly scheduled mammograms and clinical breast exams, which never found any hint of disease. So, it was especially frightening when, while on a...

HRQOL With Capivasertib/Fulvestrant vs Placebo/Fulvestrant in Advanced Breast Cancer: Analysis From CAPItello-291 Trial

As reported in The Lancet Oncology by Oliveira et al, patient-reported outcomes in the phase III CAPItello-291 trial indicate a delay in deterioration of health-related quality of life (HRQOL) with capivasertib/fulvestrant vs placebo/fulvestrant in patients with previously treated hormone...

Hematologic Malignancies
Leukemia

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin

Cardio-oncology
Lymphoma

New Studies Explore Relationships Between Heart Failure and Lymphoma, Arterial Thromboembolism and Cancer

In two studies recently reported in JACC: CardioOncology, Upshaw and colleagues1 examined the impact of preexisting heart failure on mortality in older patients in the United States with newly diagnosed Hodgkin lymphoma, and Gon and colleagues2 analyzed the incidence and impact of arterial...

Advertisement

HARMONi-2: Ivonescimab Outperforms Pembrolizumab as First-Line Treatment in NSCLC

In a phase III study conducted in China, the bispecific antibody ivonescimab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with the PD-1 inhibitor pembrolizumab as a first-line treatment of PD-L1–positive advanced non–small cell ...

ASCO Post X Feed
Social Media Hub by Everwall